Main competitors
1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Visibility Nbr of analysts
4
28
22
28
18
21
22
24
29
27
26
25
19
23
15
16
15
15
17
Average 21
Weighted average by Cap. 24
Other Pharmaceuticals